Zacks Research Has Negative Outlook for TMO Q2 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Research analysts at Zacks Research dropped their Q2 2026 earnings per share estimates for Thermo Fisher Scientific in a report issued on Wednesday, September 10th. Zacks Research analyst Team now anticipates that the medical research company will post earnings per share of $5.92 for the quarter, down from their prior estimate of $6.01. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q4 2026 earnings at $6.51 EPS, FY2026 earnings at $24.13 EPS, Q2 2027 earnings at $7.11 EPS and FY2027 earnings at $27.13 EPS.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.Thermo Fisher Scientific’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS.

Several other equities research analysts also recently issued reports on TMO. UBS Group raised their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $490.00 to $550.00 in a research report on Thursday. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Finally, Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $592.24.

Thermo Fisher Scientific Trading Down 2.4%

Shares of TMO stock opened at $479.48 on Thursday. The firm has a 50 day moving average price of $466.86 and a two-hundred day moving average price of $451.65. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $181.06 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 2.62 and a beta of 0.75. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $623.77.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently modified their holdings of the business. NWF Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $377,000. Reynders McVeigh Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 0.5% in the second quarter. Reynders McVeigh Capital Management LLC now owns 9,710 shares of the medical research company’s stock valued at $3,937,000 after buying an additional 45 shares during the period. SevenBridge Financial Group LLC lifted its holdings in Thermo Fisher Scientific by 38.3% in the second quarter. SevenBridge Financial Group LLC now owns 4,955 shares of the medical research company’s stock valued at $2,009,000 after buying an additional 1,371 shares during the period. Osaic Holdings Inc. lifted its holdings in Thermo Fisher Scientific by 35.7% in the second quarter. Osaic Holdings Inc. now owns 67,715 shares of the medical research company’s stock valued at $28,572,000 after buying an additional 17,806 shares during the period. Finally, American Trust lifted its holdings in Thermo Fisher Scientific by 1.7% in the second quarter. American Trust now owns 5,663 shares of the medical research company’s stock valued at $2,296,000 after buying an additional 93 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.